We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 16 for:    orbit II
Previous Study | Return to List | Next Study

Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions (ORBIT II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01092416
Recruitment Status : Completed
First Posted : March 25, 2010
Results First Posted : January 6, 2016
Last Update Posted : February 12, 2020
Information provided by (Responsible Party):
Cardiovascular Systems Inc

Brief Summary:
This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects. Study is going to enroll up to 429 subjects in up to 50 U.S. study sites. The primary safety endpoint is 30-day MACE and primary efficacy endpoint is procedural success. All subjects will be treated with the orbital atherectomy system and adjunctive stent. All subjects will be followed in clinic at 30 days. Additionally, all subjects will have an annual phone call or clinical follow up at each anniversary until study is closed.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Device: Diamondback 360 Orbital Atherectomy System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 443 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360°® Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II)
Study Start Date : May 2010
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Safety

Intervention Details:
  • Device: Diamondback 360 Orbital Atherectomy System
    Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.

Primary Outcome Measures :
  1. Primary Safety Endpoint: 30-Day Freedom From Major Adverse Cardiac Events (MACE) [ Time Frame: 30 days ]

    OAS safety was measured by a composite of MACE at 30-days post procedure. MACE is composed of:

    • Cardiac death.
    • MI - defined as a CK-MB level > 3 times the upper limit of lab normal (ULN) value with or without new pathologic Q wave.
    • TVR - defined as revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure.

  2. Primary Efficacy Endpoint: Procedural Success [ Time Frame: Participants were followed from baseline procedure through the duration of hospital stay, an average of 33.6 hours. ]
    Procedural success was defined as success in facilitating stent delivery with a residual stenosis of <50% and without the occurrence of an in-hospital MACE in de novo, severely calcified coronary lesions.

Secondary Outcome Measures :
  1. Angiographic Success [ Time Frame: Baseline procedure, with a mean total procedure time of 52.5 minutes. ]
    Angiographic success was defined as success in facilitating stent delivery with <50% residual stenosis and without severe angiographic complications.

  2. Severe Angiographic Complications [ Time Frame: Baseline procedure, with a mean total procedure time of 52.5 minutes. ]
    Severe angiographic complications were defined as severe dissection (Type C to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow.

  3. 12-Month Freedom From Major Adverse Cardiac Events (MACE) [ Time Frame: 12 months ]
    The safety of the OAS was measured for the secondary safety endpoint consisting of a composite of freedom from MACE through 12 months of follow-up.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be 18 or older.
  • Subjects must have a clinical indication for coronary intervention.
  • CK and CK-MB must be less than or equal to the upper limit of lab normal value within 8 hours prior to the procedure.
  • The target lesion must be a de novo coronary lesion that has not been previously treated with any interventional procedure.
  • The target vessel must be a native coronary artery with a stenosis of >= 70% and < 100%.
  • The target vessel reference diameter must be >= 2.5mm and <= 4.0 mm.
  • The lesion length must not exceed 40 mm.
  • The target vessel must have a TIMI flow 3 at baseline.
  • The target lesion must have evidence of severe calcium deposit at the lesion site based on the protocol criterion.
  • The lesion must be crossable with the study guide wire.

Exclusion Criteria:

  • Inability to understand the study or a history of non-compliance with medical advice.
  • Unwilling or unable to sign the ORBIT II Informed Consent Form (ICF).
  • History of any cognitive or mental health status that would interfere with study participation.
  • Currently enrolled in any other pre-approval investigational study (does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.).
  • Female subjects who are pregnant or planning to become pregnant within the study period.
  • Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel without adequate alternative medications.
  • Known sensitivity to contrast media, which cannot be adequately pre-medicated.
  • Diagnosed with chronic renal failure or has a serum creatinine level >2.5 mg/dl.
  • Experienced acute MI (STEMI or non-STEMI: CK and CK-MB greater than 1 times the upper limit of lab normal) within 30 days prior to index procedure.
  • History of major cardiovascular intervention within 30 days.
  • Evidence of current (within 6 months) left ventricular ejection fraction ≤ 25%.
  • NYHA class III or IV heart failure.
  • History of a stroke or transient ischemic attack (TIA) within 6 months.
  • Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months.
  • History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion if one should become necessary.
  • Concurrent medical condition with a life expectancy of less than 12 months.
  • History of immune deficiency.
  • Uncontrolled insulin dependent diabetes.
  • Evidence of active infections on the day of the index procedure.
  • Subject has planned cardiovascular intervention within 60-days post index procedure.
  • Subject is not an acceptable candidate for emergent coronary artery bypass surgery.
  • Subject with known allergy to atherectomy lubricant components such as soybean oil, egg yolk phospholipids, glycerin and sodium hydroxide.
  • Subject with 3 lesions requiring intervention.
  • Subject with 2 lesions unless the treatment of the lesions is staged. The non target lesion must first be treated at least 12 hours prior to the index procedure. The subject's CK and CK-MB must be less than or equal to one times the upper limit of the lab normal value 12 ± 2 hours post procedure and there were no procedural complications during the first lesion intervention.
  • Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or LIMA/RIMA bypass.
  • Target vessel has other lesions with greater than 50% diameter stenosis based on visual estimate or on-line QCA.
  • Target vessel has angiographically visible or suspected thrombus.
  • Target vessel has a stent from previous PCI.
  • Target vessel is excessively tortuous.
  • Target lesion is an ostial location (within 5 mm of ostium) or an unprotected left main lesion.
  • Target lesion is a bifurcation.
  • Target lesion has a ≥ 1.5 mm side branch.
  • Angiographic evidence of a dissection prior to OAS treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01092416

Show Show 51 study locations
Sponsors and Collaborators
Cardiovascular Systems Inc
Layout table for investigator information
Principal Investigator: Jeffrey Chambers, MD Metropolitan Cardiology Consutants
Publications of Results:

Layout table for additonal information
Responsible Party: Cardiovascular Systems Inc
ClinicalTrials.gov Identifier: NCT01092416    
Other Study ID Numbers: ORBIT II
First Posted: March 25, 2010    Key Record Dates
Results First Posted: January 6, 2016
Last Update Posted: February 12, 2020
Last Verified: January 2020
Keywords provided by Cardiovascular Systems Inc:
Severely calcified lesion
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases